Binge Eating and Compulsive Buying During Cabergoline Treatment for Prolactinoma: A Case Report.

Author: BotelhoMariana Coelho, Correa E CastroAna Carolina, GadelhaMonica Roberto, NardiAntonio E, NascimentoJoão Bosco, ViolanteAlice Helena Dutra, de AraujoAndressa Alexandre, de SouzaRafaela Marchon

Paper Details 
Original Abstract of the Article :
Prolactinomas are the most prevalent functional pituitary adenomas. They are usually treated clinically with dopamine agonists. The most widely used and suitable drug is cabergoline (CAB), a specific D2 dopamine agonists. Patients in prolactinoma treatment with CAB commonly report physical side effe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178067/

データ提供:米国国立医学図書館(NLM)

Behavioral Changes Associated with Cabergoline Treatment

The field of endocrinology is constantly seeking to improve the treatment of prolactinomas, benign tumors of the pituitary gland. This research presents a case report of a 47-year-old woman who developed compulsive buying, binge eating, and hypersexuality after four years of cabergoline treatment for prolactinoma. The researchers report that the patient scored high levels on scales measuring compulsive buying, binge eating, and impulsivity. The study highlights the potential for aberrant behavioral changes, such as increased impulsivity, in patients treated with cabergoline and other dopamine agonists.

The Potential for Behavioral Side Effects

This case report highlights the potential for behavioral side effects in patients treated with cabergoline for prolactinoma. The study's findings suggest that dopamine agonists, like cabergoline, can induce aberrant behavioral changes, such as increased impulsivity and compulsive behaviors. This information is crucial for clinicians to be aware of and monitor for potential behavioral side effects in patients receiving cabergoline treatment.

The Importance of Psychiatric Monitoring

This case report underscores the importance of regular psychiatric monitoring in patients receiving cabergoline treatment. The researchers recommend that clinicians conduct specific psychiatric evaluations during treatment, especially in patients treated for several years. This proactive approach can help identify and manage potential behavioral side effects and ensure the overall well-being of patients receiving cabergoline therapy.

Dr.Camel's Conclusion

This case report, like a camel encountering a hidden oasis in the desert of prolactinoma treatment, reveals the potential for unexpected side effects of cabergoline. The researchers' findings highlight the importance of vigilant psychiatric monitoring in patients receiving this medication. By staying alert for potential behavioral changes, clinicians can ensure the best possible outcomes for patients and mitigate the risks associated with dopamine agonist therapy.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-11-02
Further Info :

Pubmed ID

35693961

DOI: Digital Object Identifier

PMC9178067

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.